Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sgp(schering plough) -- Ignore unavailable to you. Want to Upgrade?

To: Quonnie who wrote (61)	10/21/1998 12:32:00 AM
From: HiSpeed	Read Replies (3) \| Respond to of 117

^Schering-Plough Corp. Schering-Plough Corp. reported a 22 percent increase in third-quarter earnings amid stronger sales of its leading antihistamine Claritin. The Madison, N.J., pharmaceutical company posted profits of $432 million, or 58 cents a diluted share, compared with $353 million, or 48 cents, a year earlier. The results beat a First Call consensus estimate by a penny. The company also reported double-digit sales growth, with sales rising 16 percent to $1.99 billion from $1.71 billion a year ago. Foreign exchange hurt sales by two percentage points, the company said. Leading the growth in worldwide pharmaceuticals were Claritin sales, which rose 42 percent to $635 million. The antiviral/anticancer agent Intron A, which in the U.S. includes sales of Rebetron combination therapy, also made a strong showing in the quarter. Combined sales of Intron A and Rebetron combination therapy rose 33% to $202 million. Sales of Schering's leading products helped lift worldwide pharmaceutical sales 17 percent to $1.82 billion from $1.55 billion a year earlier. For the first nine months of 1998, Schering's net income increased 21 percent from $1.1 billion to $1.33 billion. Sales increased 20 percent, from $6 billion in the first nine months of 1998, compared to $4.99 billion in 1997. Schering closed at $98.50, down $1.93